Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on hela cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 3023-3028

  Wei, Xiao Qiang ^a,b   Ma, Hui Qing ^b   Liu, Ai Hong ^c   Zhang, You Zhong ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c Qingdao Haici Medical Group   (China)

Author keywords

5 ALA PDT; Combination treatment; Low dose cisplatin; Synergestic anticancer activity

Indexed keywords

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PHOTOSENSITIZING AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL CULTURE; UTERINE CERVIX TUMOR; WESTERN BLOTTING;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84880394665     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.3023     Document Type: Article

References (34)

1. Chen HM, Liu CM, Yang H, et al (2011a). 5-aminolevulinic acid induce apoptosis via NF-kappaB/JNK pathway in human oral cancer Ca9-22 cells. J Oral Pathol Med, 40, 483-9.
2. Chen X, Zhao P, Chen F, Li L, and Luo R (2011b). Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer. Lasers Med Sci, 26, 69-78.
3. Compagnin C, Mognato M, Celotti L, et al (2010). Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy. Cell Prolif, 43, 262-74.
4. Crescenzi E, Chiaviello A, Canti G, et al (2006). Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy, Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol Cancer Ther, 5, 776-85.
5. Crescenzi E, Varriale L, Iovino M, et al (2004). Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol Cancer Ther, 3, 537-44.
6. Danial NN, Korsmeyer SJ (2004). Cell death, critical control points. Cell, 116, 205-19.
7. Davila ML. (2011). Photodynamic therapy. Gastrointest Endosc Clin N Am, 21, 67-79.
8. Fu KK, DeGregorio MW, Phillips JW (1988). Plasma and tumor concentrations of cisplatin following intraperitoneal infusion or bolus injection with or without continuous low-dose-rate irradiation. NCI Monogr, 6, 123-7.
9. Garland SM, Bhatla N, Ngan HY (2012). Cervical cancer burden and prevention strategies, Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev, 21, 1414-22.
10. Ge R, Ahn JC, Shin JI, et al (2011). An in vitro and in vivo study of combination therapy with Photogem(R)-mediated photodynamic therapy and cisplatin on mouse cancer cells (CT-26). Photomed Laser Surg, 29, 155-60.
11. Gomer CJ, Dougherty TJ (1979). Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res, 39, 146-51.
12. Gui T, Wang Y, Mao Y, et al (2012). Comparisons of 5-aminolevulinic acid photodynamic therapy and afterloading radiotherapy in vivo in cervical cancer. Clin Transl Oncol, 15, 434-42.
13. He GF, Bian ML, Zhao YW, et al (2008). Apoptosis-inducing effect of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) on cervical cancer cell lines. Ai Zheng, 27, 897-904.
14. He GF, Bian ML, Zhao YW, et al (2009). A study on the mechanism of 5-aminolevulinic acid photodynamic therapy in vitro and in vivo in cervical cancer. Oncol Rep, 21, 861-8.
15. Ishizuka M, Abe F, Sano Y, et al (2011). Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol, 11, 358-65.
16. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
17. Jemal A, Murray T, Samuels A, et al (2003). Cancer statistics, 2003. CA Cancer J Clin, 53, 5-26.
18. Ke QH, Zhou SQ, Du W, et al (2012). Early efficacy of taxotere and cisplatin chemo-radiotherapy for advanced cervical cancer. Asian Pac J Cancer Prev, 13, 617-9.
19. Kim YW, Bae SM, Battogtokh G, Bang HJ, Ahn WS (2012). Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells, in vivo and in vitro studies. PLoS One, 7, e38583.
20. Lagrange JL, Bondiau PY, Tessier E, et al (1996). Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer. Int J Cancer, 68, 452-6.
21. Liu Y, Xing H, Han X, et al (2008). Apoptosis of HeLa cells induced by cisplatin and its mechanism. J Huazhong Univ Sci Technolog Med Sci, 28, 197-9.
22. Massague, J. (2004). G1 cell-cycle control and cancer. Nature, 432, 298-306.
23. Oleinick NL, Morris RL, Belichenko I (2002). The role of apoptosis in response to photodynamic therapy, what, where, why, and how. Photochem Photobiol Sci, 1, 1-21.
24. Peng Q, Warloe T, Berg K, et al (1997). 5-Aminolevulinic acidbased photodynamic therapy. Clinical research and future challenges. Cancer, 79, 2282-308.
25. Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33, 9-23.
26. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-36.
27. Schloffer D, Horky M, Kotala V, Wesierska-Gadek J (2003). Induction of cell cycle arrest and apoptosis in human cervix carcinoma cells during therapy by cisplatin. Cancer Detect Prev, 27, 481-93.
28. Suo Z, Lippard SJ, Johnson KA (1999). Single d(GpG)/cisdiammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry, 38, 715-26.
29. Suprasert P, Thongsong T, Srisomboon J, Chailert C (2007). Efficacy of cisplatin in early stage cervical cancer with a long waiting period for surgery. Asian Pac J Cancer Prev, 8, 51-4.
30. Tsai JC, Wu CL, Chien HF, Chen CT (2005). Reorganization of cytoskeleton induced by 5-aminolevulinic acid-mediated photodynamic therapy and its correlation with mitochondrial dysfunction. Lasers Surg Med, 36, 398-408.
31. Tsai T, Ji HT, Chiang PC, et al (2009). ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells. Lasers Surg Med, 41, 305-15.
32. Uehara M, Inokuchi T, Ikeda H (2006). Enhanced susceptibility of mouse squamous cell carcinoma to photodynamic therapy combined with low-dose administration of cisplatin. J Oral Maxillofac Surg, 64, 390-6.
33. Wesierska-Gadek J, Schloffer D, Kotala V, et al (2002). Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer, 101, 128-36.
34. Yow CM, Wong CK, Huang Z, Ho RJ (2007). Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell. Liver Int, 27, 201-8.